Markets
US-TECH
Steve Huffman, cofounder and CEO of Reddit (Frederic J. Brown/Getty Images)

Reddit soars after suing Anthropic, alleging it trained AI on personal user data without permission

While other AI companies have played by the rules, Reddit says Anthropic has officially crossed the line.

Nia Warfield

Reddit shares popped nearly 8% Tuesday afternoon after the social media platform filed a lawsuit against AI startup Anthropic. In the suit, Reddit alleges Anthropic engaged in “unlawful and unfair business acts” by using its data without permission.

Reddit alleges that Anthropic, in particular, has been using personal information from its users to train AI models.

The lawsuit, filed in San Francisco, says that other AI giants have respected the platform’s rules, which is why Reddit has entered formal licensing partnerships with companies like OpenAI and Google. Reddit has become a key player in the generative-AI boom, thanks to its massive archive of user-generated content that’s become prime training material for AI models like Anthropic’s Claude.

“While Reddit has always been of the mind that the community should be open to all humans looking for connection and community, it has never allowed its platform and the countless communities who find a home on it to be appropriated by commercial actors seeking to create billion-dollar enterprises and offering nothing in return to Reddit and its users,” the lawsuit states.

Reddit said it’s seeking damages and aims to compel Anthropic to comply with its contractual and legal obligations. Reddit shares are down about 28% year to date, but have more than doubled over the past year.

More Markets

See all Markets
(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most-searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be short hand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January more people in the US are searching for Eli Lilly’s weight loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides," a catch-all term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly's diabetes and weight loss drugs have outsold Novo's and that gap is expected to widen this year.

markets

Crypto crumble smokes bitcoin-sensitive stocks and speculative tech

It’s a rough day out there, with the pain in the crypto markets being felt among select subgroups of US equities. Shortly before 2 p.m. ET on Wednesday here’s a snapshot of where some of the worst pinches are.

There is some overlap between some of these baskets, for instance bitcoin treasury company Strategy figures both in the “bitcoin sensitive” and “meme” basket. But in general it’s just a pretty ugly day for some of the more speculative corners of the stock market.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.